OncUpdates

Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice

[OncUpdates @OncUpdates]

⭐️Multiple Myeloma Key Study Highlight from ASCO 2026 with Dr. Vincent Rajkumar

@VincentRK discusses #MajesTEC-9 w/ @OncBrothers

#multiplemyeloma #mmsm #HemOnc #OncTwitter #MedTwitter #ASCO26 @ASCO @MayoClinic @RoswellPark @IMFmyeloma

🔗 Full Video: https://t.co/0MBdirzSf0

[OncUpdates @OncUpdates]

⭐️ 5 Key #MultipleMyeloma Trial Updates from #EHA2026!

@RahulBanerjeeMD joins @OncBrothers to discuss:
1️⃣ CEPHEUS
2️⃣ MajesTEC-3
3️⃣ MajesTEC-9
4️⃣ MonumenTAL-3
5️⃣ SUCCESSOR-2

#OncTwitter #mmsm #HemOnc @UWMedicine @EHA_Hematology

🔗Full Video +summary 👇
https://t.co/SmjKH1d9Rh

[Oncology Brothers @OncBrothers]

I use Olanzapine heavily in my clinical practice across multiple tumor types. 👇👇 Phase III: Netupitant/Palonosetron + olanzapine +/- DEX was noninferior to standard 4-day DEX for CINV in highly emetogenic chemo. ⬇️ steroid toxicities.

#OncTwitter #bcsm #gusm @JCO_ASCO

[OncUpdates @OncUpdates]

🚨 FDA Approval: Perioperative Pembro + EV for #MIBC

@US_FDA approved pembro + enfortumab vedotin-ejfv for adults with muscle-invasive bladder cancer eligible for cystectomy

#OncTwitter #MedTwitter #MedX #Oncology #BladderCancer #GU #FDA #Bladder

🔗 https://t.co/yglkStKakm

[OncUpdates @OncUpdates]

⭐️ Liso-Cel in Relapsed #DLBCL: Patient Selection, Outcomes & Referral Strategies

🎙️ @JoshuaBrodyMD

✅ Survival benefit
🔑 Refer early to CAR T-cell centers
#Lymphoma #OncTwitter #MedX #MedEd #ASCO26 #MedEd

🔗 Full video discussion with summary👇
https://t.co/cjxrMzhXxc

[Oncology Brothers @OncBrothers]

We touched on R/R DLBCL in our challenging case discussion with @lymphomaphilia and #GillesSalles from @MSKCancerCenter.

But here is the list of a few CAR-T and systemic treatment options in R/R DLBCL.

#OncTwitter #HemeTwitter @OncoAlert @OncUpdates

[OncUpdates @OncUpdates]

⭐️ Emerging Data: Amivantamab & Anti-EGFR Bispecifics in #HNSCC

🎙️ Dr. Dalal + @fangdisun discuss data from #OrigAMI-4 and #OrigAMI-5 from #ASCO26

#HNSCC #hncsm #OncTwitter #MedX #MedTwitter #ASCO26 #MedEd @StanfordMed

🔗 Full video + key takeaways👇
https://t.co/ufu4HyFfkV

[Oncology Brothers @OncBrothers]

Isatuximab subcutaneously with the on-body delivery system is now @US_FDA ✅ for multiple myeloma

✅ Isa-VRd in NDMM
✅ Isa-Pd in RRMM
✅ Isa-Kd in RRMM

#Mmsm #HemeTwitter #HappyFriday @OncUpdates

[Sawyer Bawek, DO @sawyer_bawek]

⭐️#Fellowship Application Essentials: Program Director Tips from #ASCO26

🔗Full article summary 👇

#ASCOConnection #ASCO
#OncTwitter #MedTwitter #MedEd
@ASCOTECAG @hemeoncfellow @HemOncFellows #Match #Match2026 @IMG_Oncologists @CleClinicMD

[OncUpdates @OncUpdates]

⭐️ 5 Key #MultipleMyeloma Trial Updates from #EHA2026!

@RahulBanerjeeMD joins @OncBrothers to discuss:
1️⃣ CEPHEUS
2️⃣ MajesTEC-3
3️⃣ MajesTEC-9
4️⃣ MonumenTAL-3
5️⃣ SUCCESSOR-2

#OncTwitter #mmsm #HemOnc @UWMedicine @EHA_Hematology

🔗Full Video +summary 👇
https://t.co/SmjKH1d9Rh

[Oncology Brothers @OncBrothers]

In our lymphoma “Challenging Case” discussion with @lymphomaphilia & #GillesSalles we 🗣️

✅ Rx options for early R/R DLBCL
✅ Rx for follicular lymphoma->DLBCL conversion

Full 🗣️:
⭐️ https://t.co/U07Ylpzg4n
⭐️ “Oncology Brothers” podcast

#OncTwitter #lymsm #HemeTwitter

[OncUpdates @OncUpdates]

Best of luck to all the upcoming #HemOnc #Fellowship #Match applicants!

@sawyer_bawek provides an update from the @ASCO Fellowship Application Essentials session at @ASCOTECAG

🔗Full link👇

#MedTwitter #OncTwitter @HemOncFellows @jamecancerdoc #MedX @JCOOP_ASCO @CleClinicMD

[Sawyer Bawek, DO @sawyer_bawek]

💥#Fellowship Application Essentials: Program Director Tips from #ASCO26 Trainee & Early Career Lounge Panel!

⭐️Key pearls for #HemOnc applicants!

#ASCOConnection #ASCO @ASCO
#OncTwitter #MedTwitter #MedEd
@ASCOTECAG @hemeoncfellow @HemOncFellows

https://t.co/6rUCxmT8OI

[OncUpdates @OncUpdates]

🚨 Evolving Treatment Landscape in 2L & Beyond #MultipleMyeloma

🎙️ @OncBrothers 🗣️ w/ @VincentRK @Bethfaiman @Rfonsi1

🔑 Bispecifics & CAR T-> earlier lines, GPRC5D tox management; CELMoDs emerging
#mmsm #OncTwitter #MedTwitter #MedX

🔗 Full video 👇
https://t.co/0MBdirzSf0

[OncUpdates @OncUpdates]

⭐️ ASCO 2026: Key GI Trials Shaping Clinical Practice

@OncBrothers +@NVijayvergiaMD discuss:
✅ EMERALD-3
✅ FIGHT-302
✅ CIRCULATE
✅ MATTERHORN
#OncTwitter #GIonc #gism #crcsm #pcsm #MedX #MedTwitter #MedEd @ASCO #ASCO26

🎥Full discussion +summary👇
https://t.co/6rAwaWgxxA

[OncUpdates @OncUpdates]

⭐️ Liso-Cel in Relapsed #DLBCL: Patient Selection, Outcomes & Referral Strategies

🎙️ @JoshuaBrodyMD

✅ Survival benefit
🔑 Refer early to CAR T-cell centers
#Lymphoma #OncTwitter #MedX #MedEd #ASCO26 #MedEd

🔗 Full video discussion with summary👇
https://t.co/cjxrMzhXxc

[Oncology Brothers @OncBrothers]

4 studies we touched on during lymphoma highlights from #EHA2026 w/ @DrCarlaCasulo

⭐️ #frontMIND
⭐️ #POLARBEAR
⭐️ HD-MTX for CNS prophylaxis
⭐ #EPCOREFL1

#OncTwitter #HemeTwitter #lysm @OncUpdates @WilmotCancer

[OncUpdates @OncUpdates]

⭐️Talquetamab Side Effects: Management & Counseling 🩸

🎙️ @sawyer_bawek & @hhashmi87 🗣️
✅ Skin/nail: topical therapies & care routines
✅ Oral/dysgeusia: counseling & dietitian support
✅ CRS & neurotoxicity pearls
#OncTwitter #mmsm #HemOnc #ASCO26

🎥👇
https://t.co/YGAJtBGbXW

[Beth Faiman PhD @Bethfaiman]

Thank you @OncBrothers for the unique opportunity to share insights on #ASCO26 and #EHA26 updates in #myeloma!! The landscape is continually evolving these days!! #talquetamab #cereblon #bispecifics

[Oncology Brothers @OncBrothers]

Lymphoma Highlights from #EHA2026 w/ @DrCarlaCasulo

⭐️ #frontMIND
⭐️ #POLARBEAR
⭐️ HD-MTX for CNS prophylaxis
⭐ #EPCOREFL1

Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ https://t.co/aKO6zRPJMR

#HemeTwitter @OncUpdates #OncTwitter #lymsm

[OncUpdates @OncUpdates]

⭐️COMPETE Ph 3 Trial:[177Lu]Lu-edotreotide vs Everolimus in advanced progressive SSTR+ GEP-NETs

Peptide receptor radionuclide therapy significantly improved median PFS (23.9 vs 14.1 mo) with favorable safety profile compared to everolimus.

🔗 https://t.co/QgZst05iYS
#OncTwitter